Monte Rosa Therapeutics doses first patient in Phase 2 prostate study
Monte Rosa Therapeutics announces first patient dosed in MODeFIRe-1, a Phase 2 study of MRT-2359 in combination with apalutamide in AR mutation-positive metastatic castration-resistant prostate cancer.